SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA. More information about this event, including access to the live, audio-only webcast, may be accessed ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style ...

Shares of ResMed (RMD) have been strong performers lately, with the stock up 7.1% over the past month. The stock hit a new 52-week high of $260.49 in the previous session. ResMed has gained 48.9% since the start of the year compared to the 5.1% move for the Zacks Medical sector and the 12.8% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last fo ...

On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating the consensus of $1.18 billion, driven by increased demand for sleep devices and masks portfolio and strong growth across the Residential Care Software business. Residential Care Software revenue increased by 12% on a constant currency basis, reflecting continued organic growth in the Residential Care Software portfolio ...

ResMed Inc.’s (RMD) adjusted earnings per share (EPS) in the first quarter of fiscal 2025 were $2.20, up 34.1% year over year. The metric beat the Zacks Consensus Estimate by 8.4%.The adjustments include certain non-recurring expenses/benefits like the amortization of acquired intangibles, along with the income tax effect on those adjustments.GAAP EPS in the reported quarter was $2.11, up 41.6% from the year-ago level.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the annou ...

财务数据和关键指标变化 - 公司第一季度的总收入为12.2亿美元，同比增长11% [25] - 净收入增长35%，非GAAP稀释每股收益增长34% [29] - 毛利率提高320个基点，达到59.2% [27] 各条业务线数据和关键指标变化 - 设备销售同比增长10%，面罩及其他销售增长11% [26] - 住宅护理软件收入增长12% [26] - 面罩及配件在美国、加拿大和拉丁美洲的销售增长10% [45] 各个市场数据和关键指标变化 - 美国、加拿大和拉丁美洲的设备销售增长11% [26] - 欧洲、亚洲及其他地区的设备销售增长9% [26] - 全球设备销售增长10% [26] 公司战略和发展方向和行业竞争 - 公司致力于通过云连接医疗设备、数字健康平台等技术改善患者健康 [5][16] - 公司计划在2030年前帮助超过5亿人实现更好的睡眠和呼吸健康 [23] - 公司在竞争中保持市场领导地位，尤其是在AirSense 10和AirSense 11平台上 [7][14] 管理层对经营环境和未来前景的评论 - 管理层对未来的市场需求持乐观态度，认为消费者可穿戴设备和GLP-1药物将为公司带来积极影响 [11][12] - 管理层强调持续的创新和数字健康生态系统将推动长期增长 [24] 其他重要信息 - 公司计划在2025财年继续进行股票回购，每季度回购约7500万美元的股票 [30] - 公司在新产品推出方面表现积极，特别是即将推出的AirTouch N30i面罩 [8][9] 问答环节所有提问和回答 问题: 新面罩的预订情况如何 - 管理层表示目前预订情况不显著，但对新技术的市场反应充满期待 [32][33] 问题: 关于全球设备增长的驱动因素 - 管理层指出，设备增长主要来自于新患者需求和市场份额的提升 [37][41] 问题: 面罩销售的驱动因素 - 管理层认为，面罩销售增长主要得益于新患者流入和ReSupply计划的扩展 [45][46] 问题: 竞争环境的变化 - 管理层表示，竞争依然激烈，但公司在市场中保持了良好的表现 [81][90] 问题: AirSense 11的生产情况 - 管理层确认AirSense 11的生产正在顺利进行，并预计在年底前不再受限于分配 [86][87]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.004 per share RMD New York Stock Exchange FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT ...

文章核心观点 - 公司第三季度收入为12.2亿美元,同比增长11.1% [1] - 每股收益为2.20美元,高于上年同期的1.64美元,同比增长8.37% [1] - 公司各个业务板块收入均实现两位数增长 [1] 按目录分类总结 美国、加拿大和拉丁美洲市场 - 设备收入为3.845亿美元,同比增长11.2% [1] - 面罩及其他收入为3.228亿美元,同比增长10.4% [1] - 该地区总收入为7.073亿美元,同比增长10.8% [1] 欧洲、亚洲及其他市场 - 总收入为3.604亿美元,同比增长11% [1] - 设备收入为2.413亿美元,同比增长10.3% [1] - 面罩及其他收入为1.192亿美元,同比增长12.7% [1] 全球收入 - 设备总收入为6.258亿美元,同比增长10.8% [1] - 软件即服务收入为1.568亿美元,同比增长12.6% [1] - 睡眠及呼吸护理总收入为10.7亿美元,同比增长10.9% [1] - 面罩及其他总收入为4.42亿美元,同比增长11% [1]

ResMed (RMD) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.37%. A quarter ago, it was expected that this maker of medical products for respiratory disorders would post earnings of $2.03 per share when it actually produced earnings of $2.08, delivering a surprise of 2.46%.Over the ...